Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer
Authors:
- Corinne MolyneuxCMCorinne Molyneux
- Rhianna O'SUllivanRORhianna O'SUllivan
- Eoghan J. Mulholland-IllingworthEMEoghan J. Mulholland-Illingworth
- Joshua W. MooreJMJoshua W. Moore
- Nick LiNLNick Li
- Petra VlckovaPVPetra Vlckova
- Raheleh AmirkhahRARaheleh Amirkhah
- Aurelie DobricADAurelie Dobric
- Shauna CrampsieSCShauna Crampsie
Preprint
Abstract
Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.Keywords
All Related Versions
Funding Information
- The Constance Travis Charitable Trust
- Biotechnology and Biological Sciences Research Council
- Cancer Research UK City of London Centre (CTRQQR-2021/100004)
- University College London Hospitals NHS Foundation Trust BRC (BRC422)
- Lee Placito Research Fellowship